Drugs / 18F-FDS
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02450942 | Jan 2015 → Jan 2018 | bacterial infectious disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-FDS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02450942 ↗ |
| Known as | (18)F-2-fluorodeoxy sorbitol | “The recently reported (18)F-FDS ((18)F-2-fluorodeoxy sorbitol) as a PET (positron emission tomography) tracer can be used to image Enterobacteriaceae-specific infections and...” PMID 26924501 ↗ Dec 2015 |
| Modality | Diagnostic / imaging agent | “The recently reported (18)F-FDS ((18)F-2-fluorodeoxy sorbitol) as a PET (positron emission tomography) tracer can be used to image Enterobacteriaceae-specific infections” PMID 26924501 ↗ Dec 2015 |
| Route | Intravenous | “18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans” NCT02450942 ↗ |